Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026)
Ardelyx (ARDX) posted Cash from Investing Activities of -$10.0 million for Q1 2026, down 364.7% on a QoQ basis from $3.8 million in Q4 2025, and down 450.58% year-over-year from $2.9 million in Q1 2025.
Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Ardelyx's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$10.0 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 450.58% year-over-year to -$10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.8 million (down 69.1% YoY) and the FY2025 annual result came in at -$9.0 million, up 51.09% from the prior year.
- Cash from Investing Activities was -$10.0 million for Q1 2026 at Ardelyx, down from $3.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $34.9 million in Q2 2025 and bottomed at -$59.2 million in Q2 2023.
- A 5-year average of -$8.8 million and a median of -$832000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 3829.93% — and 2025, when it jumped 210.85%.
- Ardelyx's Cash from Investing Activities stood at $1.4 million in 2022, then plunged by 2151.84% to -$29.6 million in 2023, then tumbled by 40.77% to -$41.6 million in 2024, then jumped by 109.07% to $3.8 million in 2025, then plunged by 364.7% to -$10.0 million in 2026.
- Business Quant data shows ARDX's Cash from Investing Activities at -$10.0 million in Q1 2026, $3.8 million in Q4 2025, and -$50.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | -10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.00 Mn |
| Mar 31, 2026 | -10.00 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Mar 31, 2024 | -2.57 Mn |
| Mar 31, 2024 | -2.57 Mn |
| Dec 31, 2023 | -29.57 Mn |
| Dec 31, 2023 | -29.57 Mn |